Immune Cell Assays
Immuno-oncology has emerged as one of the most promising treatments for cancer, either alone or in combination with other therapies. These therapies activate the immune system to destroy cancerous cells either by targeting stimulatory receptors or by inhibiting key checkpoints in the T-cell immune response. With growing interest and applications of clinical trial testing of these checkpoint inhibitors, we have built an expert team to focus on the critical interactions between the immune system and immuno-oncology drugs such as, PD-1 and PD-L1 inhibitors.
In order to accurately characterize immune cell interactions during the development process, our team is available to offer the following assays:
More From Less
BioOutsource employs the iQue Screener PLUS to examine multiple readouts within a single assay, reducing the time and requirement for sample. Our scientific team works to optimize your process and accurately interpret critical data. Combining phenotypic and functional readouts in a single measurement, assays can be designed to suit your molecule.
Contact our experts now to discuss your requirements for your molecule.